Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.

Journal of Neuro-oncology
Maria DemestreAndreas Kurtz

Abstract

Plexiform neurofibromas (PNF), one of the major features of neurofibromatosis type 1 (NF1), are characterized by complex cellular composition and mostly slow but variable growth patterns. In this study, we examined the effect of imatinib mesylate, a receptor tyrosine kinase inhibitor, on PNF-derived Schwann cells and PNF tumour growth in vitro and in vivo. In vitro, PNF-derived primary Schwann cells express platelet-derived growth factors receptors (PDGFR) alpha and beta, both targets of imatinib, and cell viability was reduced by imatinib mesylate, with 50% inhibition concentration (IC(50)) of 10 microM. For in vivo studies, PNF tumour fragments xenografted onto the sciatic nerve of athymic nude mice were first characterized. The tumours persisted for at least 63 days and maintained typical characteristics of PNFs such as complex cellular composition, low proliferation rate and angiogenesis. A transient enlargement of the graft size was due to inflammation by host cells. Treatment with imatinib mesylate at a daily dose of 75 mg/kg for 4 weeks reduced the graft size by an average of 80% (n = 8), significantly different from the original sizes within the group and from sizes of the grafts in 11 untreated mice in the control grou...Continue Reading

References

Jul 2, 1997·JAMA : the Journal of the American Medical Association·D H GutmannD Viskochil
May 16, 2002·Journal of Medical Genetics·D G R EvansA Moran
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Jul 9, 2004·Journal of Biomedicine & Biotechnology·Dusica Babovic-VuksanovicJeffrey L. Platt
Aug 29, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Sébastien BihorelJean-Michel Scherrmann
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators

❮ Previous
Next ❯

Citations

Mar 30, 2018·The Journal of Clinical Investigation·Chung-Ping LiaoLu Q Le
Apr 19, 2018·Expert Opinion on Therapeutic Targets·James A Walker, Meena Upadhyaya
Nov 1, 2013·Journal of Neuro-oncology·Wei JiangLan Kluwe
Jul 30, 2018·BMC Research Notes·Susan Fischer-HuchzermeyerAnja Harder
Apr 5, 2017·Khirurgiia·A G KrigerYu S Gal'china
Apr 29, 2015·Current Treatment Options in Neurology·Caterina SabatiniSusanna Esposito
Jul 16, 2013·International Journal of Endocrinology and Metabolism·Gul BanoStephen Schey
Apr 11, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Parag P PatwardhanGary K Schwartz
Aug 31, 2019·Dermatologic Clinics·Benjamin Becker, Roy E Strowd
Aug 12, 2021·Indian Journal of Dermatology, Venereology and Leprology·Kaberi Feroze, Feroze Kaliyadan
Dec 22, 2021·Expert Opinion on Investigational Drugs·Simge AcarAngela C Hirbe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.